Website Information
    Web Site Information :.   Site Info    Whois    Traceroute    RBL Check  

Enter Web Site URL Address:
 

tol101.org: Tolera Therapeutics - Bringing Targeted and Safer Therapies to Market
Tolera Therapeutics is developing novel therapies and technologies, to offer patients and their doctors, targeted and safer solutions, for immune modulation and related medical needs.  
 
 

Tolera Therapeutics - Bringing Targeted and Safer Therapies to Market

Description: Tolera Therapeutics is developing novel therapies and technologies, to offer patients and their doctors, targeted and safer solutions, for immune modulation and related medical needs.

Keywords: Tolera therapeutics immune modulation tolerance induction diagnosis organ transplant transplantation oncology anti-rejection therapy induction Cleveland clinic innovations investors investment Maria Siemionow

Tags: tol101, tolera, therapeutics, therapies, safer, targeted, bringing, market, immune, modulation, pipeline, news, product, therapy, rejection, transplant, organ, drug, contact, home, induction, oncology, related, developing, anti, orphan, granted, designation, patients, novel, company, articles, terms, policy, markets, privacy, brochure, conditions, medical, doctors,

Tol101.org

Content Revalency: Title: 55.56%   Description: 77.27%   Keywords: 52.38%  |  Document size: 7,167 bytes
More info: Whois - Trace Route - RBL Check
 
TOL101.ORG - Site Location
Country/Flag US United States
City/Region/Zip Code Gilbert, AZ, 85233
Organization GoDaddy.com, LLC
Internet Service Provider GoDaddy.com, LLC
 
TOL101.ORG - DNS Information
IP Address 64.202.189.170 ~ Whois - Trace Route - RBL Check
Domain Name Servers ns27.domaincontrol.com   97.74.103.14
Mail Exchange smtp.secureserver.net   92.204.80.0
mailstore1.secureserver.net   92.204.80.3
 
Site Response Header
Response HTTP/1.1 301 Moved Permanently
Server Microsoft-IIS/6.0
Date Sun, 17 Apr 2011 18:07:41 GMT
Content-Type text/html


  IP Index    TLD Index    Domain Index    Site Index New   Copyright © 2024 Cybernet Quest.